Articles filed under Living with MBC.
Here at METUPUK, we know drug access is a big issue for all metastatic breast cancer patients. There have been huge leaps and bounds made in terms of research, knowledge and potential treatment…
Read more
We are heartbroken to share the news that Tassia Haines has died. A member of METUPUK and our Executive Lead for Wales, Tass had been a significant campaigner for MBC patients since her own diagnosis…
Read more
METUPUK are delighted by the National Institute of Clinical Excellence (NICE) decision to recommend Talazoparib (Talzenna ®, Pfizer Ltd.) for treating HER2-negative, locally advanced or metastatic…
Read more
Living with an incurable form of cancer presents lots of physical, emotional and mental challenges not least of which are the expectations and pressures associated with annual celebrations and…
Read more
Sadly our Kit @Diamondtrees11 died on Monday 7th May. Her husband Phillip contacted us with the tragic news. We didn’t meet Kit but she was an integral part of METUPUK supporting us with writing…
Read more
In September last year, one of our Trustees Louise Furneaux died from metastatic breast cancer. She was a valued member of METUPUK and was our most recently appointed trustee. She helped organise…
Read more
Birthday and cancerversaries became bittersweet as I was dealing with the realities of cancer, the side effects, the constant fear of the unknown, the helplessness, the indignity of losing who you…
Read more
Many of our followers on social media will remember Mary Huckle and her tireless campaigning for #metastaticbreastcancer awareness. This blog post is the last content she wrote for us, a year ago for…
Read more
“As long as you are breathing, there is more right with you than there is wrong…..”
Read more
METUPUK historically maintained their own in-house clinical trial database for metastatic trials in the UK as there was no one source that contained them all. It used the key sites used across the…
Read more
METUPUK welcomes the approval of Piqray (alpelisib) plus fulvestrant for the treatment of hormone receptor-positive, HER2-negative, PIK3CA- mutated advanced breast cancer. Piqray is an exciting new…
Read more
METUPUK are delighted that NICE has accepted Trodelvy (sacituzumab govitecan) for routine use on the NHS in England for the treatment of patients with unresectable locally advanced or metastatic…
Read more
